Checkpoint Blockade in the Adjuvant and Neoadjuvant Settings: Key Considerations for the Surgical Oncologist
Virtual Tumor Board
Click the "View Activity" button to view this activity.View Activity
CME/CE is no longer available for this activity
• Describe the mechanistic rationale for the role of immunotherapies in earlier stage gastric and esophageal cancer
• Summarize available and ongoing clinical trial data on the use of immune checkpoint inhibitors as adjuvant or neoadjuvant therapy in resectable gastric and esophageal cancers
• Translate the latest clinical trial data to identify appropriate patients with significant recurrence risk who may benefit from approved or emerging uses of neoadjuvant or adjuvant immunotherapy
• Assess emerging biomarkers for ICIs in the early disease setting and their potential predictive role in assessing long term benefits
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
Brooke Army Medical Center